PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics to Present at Biocentury's Newsmakers in the Biotech Industry Conference
ROCKVILLE, MD --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive Officer Rachel King will present at BioCentury's Newsmakers in the Biotech Industry Conference. The presentation will take place on Friday, September 8, 2017 at 1:30 p.m.
View HTML
Toggle Summary GlycoMimetics Reports Program Updates and Second Quarter 2017 Results
FDA granted Breakthrough Therapy designation to the Company's drug candidate, GMI-1271, for treatment of adults with relapsed/refractory acute myeloid leukemia (AML) Company completed enrollment in the in Phase 2 portion of its Phase 1/2 trial of GMI-1271 for the treatment of AML Clinicians
View HTML
Toggle Summary GlycoMimetics to Receive European Patent for GMI-1271
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Patent Office has issued an "intention to grant" letter for European Patent Application Number EP12813711.1, titled "E-Selectin Antagonist Compounds, Compositions, and Methods of Use." This
View HTML
Toggle Summary GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors
ROCKVILLE, Md. --(BUSINESS WIRE)--Jun. 12, 2017-- GlycoMimetics , Inc. (NASDAQ:GLYC) announced today the appointment of Patricia S. Andrews, chief executive officer and director of Boston Biomedical, Inc. , to its Board of Directors. “It’s an asset to our Board and GlycoMimetics as a whole to be
View HTML
Toggle Summary GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2017 Global Healthcare Conference in New York City , on Wednesday, June 7, 2017 , at 2:00 p.m. ET .
View HTML
Toggle Summary GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting
Remission rates continue to be higher than historical controls and induction-related mortality continues to be lower than historical controls GMI-1271 continues to be well tolerated in combination with induction chemotherapy Only one case of severe (Grade 3/4) mucositis reported among 79 patients
View HTML
Toggle Summary GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271
Clinical trial now fully enrolled with 91 patients: 25 in newly diagnosed arm and 66 in relapsed refractory arm Interim data to be presented at ASCO and EHA Meetings showing high remission rates with acceptable tolerability Patients with higher levels of novel biomarker were more likely to achieve
View HTML
Toggle Summary GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics , Inc. (NASDAQ: GLYC) today announced the closing of its underwritten public offering of 8,050,000 shares of its common stock at a public offering price of $11.50 per share, which includes the exercise in full by the underwriters of their option to
View HTML
Toggle Summary GlycoMimetics' GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Commission , based on a favorable recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products , has granted orphan designation for the company's drug candidate
View HTML
Toggle Summary GlycoMimetics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to
View HTML